Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Opioid Use Disorder (OUD) Market, by Drug Class
1.4.2 LAMEA Opioid Use Disorder (OUD) Market, by Route of Administration
1.4.3 LAMEA Opioid Use Disorder (OUD) Market, by Distribution Channel
1.4.4 LAMEA Opioid Use Disorder (OUD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Opioid Use Disorder (OUD) Market
Chapter 4. LAMEA Opioid Use Disorder (OUD) Market by Drug Class
4.1 LAMEA Buprenorphine Market by Country
4.2 LAMEA Methadone Market by Country
4.3 LAMEA Naltrexone Market by Country
Chapter 5. LAMEA Opioid Use Disorder (OUD) Market by Route of Administration
5.1 LAMEA Parenteral Market by Country
5.2 LAMEA Oral Market by Country
Chapter 6. LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel
6.1 LAMEA Hospital Pharmacies Market by Country
6.2 LAMEA Retail Pharmacies & Stores Market by Country
6.3 LAMEA Online Pharmacies Market by Country
Chapter 7. LAMEA Opioid Use Disorder (OUD) Market by Country
7.1 Brazil Opioid Use Disorder (OUD) Market
7.1.1 Brazil Opioid Use Disorder (OUD) Market by Drug Class
7.1.2 Brazil Opioid Use Disorder (OUD) Market by Route of Administration
7.1.3 Brazil Opioid Use Disorder (OUD) Market by Distribution Channel
7.2 Argentina Opioid Use Disorder (OUD) Market
7.2.1 Argentina Opioid Use Disorder (OUD) Market by Drug Class
7.2.2 Argentina Opioid Use Disorder (OUD) Market by Route of Administration
7.2.3 Argentina Opioid Use Disorder (OUD) Market by Distribution Channel
7.3 UAE Opioid Use Disorder (OUD) Market
7.3.1 UAE Opioid Use Disorder (OUD) Market by Drug Class
7.3.2 UAE Opioid Use Disorder (OUD) Market by Route of Administration
7.3.3 UAE Opioid Use Disorder (OUD) Market by Distribution Channel
7.4 Saudi Arabia Opioid Use Disorder (OUD) Market
7.4.1 Saudi Arabia Opioid Use Disorder (OUD) Market by Drug Class
7.4.2 Saudi Arabia Opioid Use Disorder (OUD) Market by Route of Administration
7.4.3 Saudi Arabia Opioid Use Disorder (OUD) Market by Distribution Channel
7.5 South Africa Opioid Use Disorder (OUD) Market
7.5.1 South Africa Opioid Use Disorder (OUD) Market by Drug Class
7.5.2 South Africa Opioid Use Disorder (OUD) Market by Route of Administration
7.5.3 South Africa Opioid Use Disorder (OUD) Market by Distribution Channel
7.6 Nigeria Opioid Use Disorder (OUD) Market
7.6.1 Nigeria Opioid Use Disorder (OUD) Market by Drug Class
7.6.2 Nigeria Opioid Use Disorder (OUD) Market by Route of Administration
7.6.3 Nigeria Opioid Use Disorder (OUD) Market by Distribution Channel
7.7 Rest of LAMEA Opioid Use Disorder (OUD) Market
7.7.1 Rest of LAMEA Opioid Use Disorder (OUD) Market by Drug Class
7.7.2 Rest of LAMEA Opioid Use Disorder (OUD) Market by Route of Administration
7.7.3 Rest of LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Indivior PLC (Reckitt Benckiser Group plc)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Product and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.3 Orexo AB (Orexo US, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Alkermes PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.5 Titan Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Trials and Approvals:
8.6 Camurus AB
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Trials and Approvals:
8.7 AstraZeneca PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.8 Hikma Pharmaceuticals PLC
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Product Launches and Product Expansions:
8.9 Mallinckrodt PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Viatris, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental Analysis
8.10.4 Research & Development Expense
Unique Offerings 